(MENAFN- Straits Research)
Europe Aesthetic Medicine Market Size
The global aesthetic medicine market size was valued at USD 8.12 billion in 2025 and is projected to reach from USD 8.83 billion in 2026 to USD 17.35 billion by 2034, growing at a CAGR of 8.8% during the forecast period (2026-2034). with an expected valuation of USD 124.34 billion Europe is the third largest market of Aesthetic medicines. For the period of 2026 to 2034, the CAGR of Aesthetic Medicines is expected to be 14.71% for the European market.
Aesthetic treatments, often known as cosmetic treatments, are non-surgical procedures that are intended to reduce the appearance of wrinkles, renew the skin, and make it look younger. Fine line and wrinkle reduction, fat reduction, stretch mark cures, scar therapy, skin oxygenation and resurrection, body contouring and firming botulinum toxin, and skin repair are all covered under medical aesthetics. Aesthetic medicine is primarily concerned with modifying a person's visual look to their liking. Scars, excess fat, skin discoloration, skin laxity, moles, and wrinkles are all treated with this procedure.
A variety of invasive, minimally invasive, and non-invasive cosmetic procedures are used in aesthetic medicine. The global medical aesthetics market is growing as the aged population becomes more aware of such treatments and accepts novel treatments. Furthermore, evolving consumer attitudes around wellness, beauty, and healthy aging have increased aesthetic awareness and acceptability, boosting demand from new patient categories like men and millennials.
Download a Free Sample To learn more about this report,
Europe Aesthetic Medicine Market Drivers
Rhinoplasty, facelifts, neck lifts, eyelid surgery, and eye lifts have all seen a considerable increase in popularity. According to an Allergan poll conducted in April 2020, 95% of respondents said they planned to use a neurotoxic filler treatment once COVID-19 restrictions are lifted.
Many dermatologists feel the lockdowns will help patients return after the pandemic. Following the lockdowns in the United Kingdom, for example, the number of first-time visitors to dermatology clinics jumped by 78 percent.
Between the ages of 25 and 30, wrinkles, loss of skin suppleness, and dark spots appear, and between the years of 30 and 65, wrinkles, loss of skin suppleness, and dark patches become more evident. As a result, a big population vulnerable to various indications of ageing is driving up demand for aesthetic medicines. According to the CIA World Factbook, in 2018, roughly 30.5 percent of the total German population was aged 25 to 54, and around 13.6 percent of the population was aged 55 to 65. As a result, the market for aesthetic medicine is predicted to expand at a constant rate among adults aged 25 to 65.
In 2019, the English government launched a campaign to raise awareness about botched cosmetic surgeries and their impact on a person's physical and emotional health. As a result of the increased awareness of non-invasive cosmetic treatment methods, the non-invasive aesthetic treatment market in Europe is growing. A number of companies are developing advanced non-invasive aesthetic therapy products. As a result, the market is being fueled by the availability of user-friendly, technologically improved non-invasive aesthetic treatment solutions.
In Europe, there is a huge increase in demand for cosmetic operations. This is due to the region's well-functioning healthcare facilities. Non-invasive beauty treatments are becoming more popular as people become more aware of their overall fitness and look. Breast augmentation, breast reduction, and laser treatment are the most prevalent cosmetic procedures in the United Kingdom. Most of the European Countries have an ageing population which further boosts the demand for aesthetic medicines.
Furthermore, the United Kingdom's government has not established any non-surgical laser treatment regulations. This means that there are no limitations on who can perform laser tattoo removal or hair removal treatments, or what equipment can be utilized. As a result, providers are more likely to develop MedSpa and private clinics to deliver these therapies.
Market Restraints
Due to increased internet purchases, the cosmeceuticals (self-care) market had a slight effect during the pandemic. Invasive and minimally invasive needs, such as aesthetic operations, saw a significant impact as a result of aesthetic facility closures and appointment postponement. The non-invasive market, which includes injectable fillers and laser-based cosmetic treatments, has experienced moderate-to-high consequences but is predicted to recover at a moderate-to-high rate.
Furthermore, according to a survey conducted by Hamilton Fraser Cosmetic Insurance Company, 99.78 percent of surveyed aesthetic practitioners in the UK stated that COVID-19 had a significant impact on their operations, 86 percent reported a decrease in revenue, and 72 percent stated that they did not have a contingency plan in place to deal with the pandemic.
Private and government insurance policies may not cover all aesthetic operations. Methods primarily aimed at removing wrinkles, fats, hair removal, tattoo removal, removal of extra skin, and liposuction for the purpose of improving one's external appearance are not covered. Medicines include facial reconstructive after an accident and weight loss surgery to alleviate obesity-related concerns. The percentage of surgical treatments justified by medical reasons is smaller than the percentage of procedures undertaken for cosmetic reasons. As a result, a lack of reimbursement coverage for most operations may limit the market's total growth.
Market Opportunities
During the projected period, technological advancements provide attractive prospects for market participants. Furthermore, the critical need to optimize imaging workflows will boost the aesthetic medicine market's future growth rate.
Europe Aesthetic Medicine Market Segmentation Analysis
By Procedure Type
The Europe Aesthetic Medicine Market is segmented into Invasive Procedures and Non-invasive Procedures. Invasive procedures include surgical treatments such as breast augmentation, liposuction, nose reshaping, eyelid surgery, tummy tuck, and other procedures requiring surgical intervention and specialized clinical facilities. Non-invasive procedures include Botox injections, soft tissue fillers, chemical peels, laser hair removal, microdermabrasion, and other treatments that generally involve limited downtime and less extensive intervention. Invasive procedures represent a major share of the European market, while non-invasive procedures are experiencing strong demand because of their convenience, shorter recovery periods, improving treatment outcomes, and increasing consumer acceptance.
Growing aesthetic awareness, rising disposable incomes, an aging population, technological advancements, and increasing acceptance of cosmetic treatments are supporting demand for both procedure categories across Europe. The growing preference for minimally invasive treatments is encouraging consumers to choose procedures that allow faster return to daily activities, while improvements in surgical techniques and clinical infrastructure continue to support invasive procedures. Medical tourism, social media influence, expanding aesthetic clinics, and the availability of advanced treatment technologies are further contributing to market expansion across major European countries.
Request Customization to receive a tailored report.
By End Use
The Europe Aesthetic Medicine Market is segmented into Hospitals, Clinics & Aesthetic Centers, and Medspas. Hospitals provide advanced infrastructure for complex surgical and medically supervised aesthetic procedures, while clinics and aesthetic centers offer a broad range of invasive, minimally invasive, and non-invasive treatments, including injectables, laser treatments, skin rejuvenation, and body contouring. Medspas combine aesthetic treatments with wellness and personal-care services and are increasingly attracting consumers seeking convenient and personalized procedures. Clinics and aesthetic centers represent a major end-use category because of their specialized services, accessibility, and ability to provide diverse aesthetic treatments.
Increasing consumer preference for personalized aesthetic treatments, rising medical tourism, expansion of specialized aesthetic facilities, and growing acceptance of cosmetic procedures are supporting demand across hospitals, clinics and aesthetic centers, and medspas. Hospitals continue to benefit from demand for complex procedures requiring advanced medical infrastructure, while clinics and aesthetic centers are supported by the growing popularity of non-invasive and minimally invasive treatments. Medspas are also gaining traction as consumers increasingly seek convenient, wellness-oriented, and personalized aesthetic services. Rising disposable incomes, an aging population, social media influence, and advances in aesthetic technologies are expected to further strengthen demand across these end-use settings.
Speak to an Analyst to discuss market opportunities.
List of Key and Emerging Players in Europe Aesthetic Medicine Market
Evolus Inc.
AIVITA Biomedical
Ellman International, Inc.
Genesis Biosystems, Inc.
Lumenis Ltd.
Sciton, Inc.
Wells Johnson Company
Zeltiq Aesthetics, Inc.
Key Industry Developments
March 2026 – Merz Aesthetics introduced new digital education and treatment optimization programs across Europe to support physicians using its botulinum toxin and dermal filler portfolio, enhancing patient outcomes and clinical adoption.
September 2025 – Croma-Pharma expanded its facial aesthetics portfolio across Europe with new minimally invasive rejuvenation solutions, reinforcing its position in the region's growing aesthetic medicine market.
May 2025 – Sinclair strengthened its European aesthetic medicine business by expanding the commercialization of advanced collagen-stimulating injectable treatments to address increasing demand for non-surgical facial rejuvenation.
February 2025 – AbbVie expanded the European reach of its Allergan Aesthetics portfolio through new physician training initiatives and broader access to facial injectables and body contouring technologies.
Report Scope
Comments
No comment